

REMARKS

This supplemental amendment and response, in addition to the amendment and response filed October 31, 2007, responds to the Office Action mailed on October 17, 2007.

Claims 30 and 31 are added. No claims are amended or canceled. As a result, claims 1, 4, 7-22, 25, and 27-31 are now pending in this application.

Applicant has added two new claims in this response. New claims 30 and 31 include the limitation of identifying the non-inflammatory acne or acne lesions. Examples 1 and 2 (paragraphs [0044] and [0045] on page 4) provide support for this limitation; the number of non-inflammatory lesions at baseline were identified before treatment with dapsone.

CONCLUSION

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (612) 371-2106 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

DAVID W. OSBORNE

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 371-2106

Date Dec. 5, 2007

By Karen L. Himmel
Karen L. Himmel
Reg. No. 58,663

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 5th day of December, 2007.

Dawn M. Boke
Name

Dawn M. Boke
Signature